Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Berlex Oncology |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00505921 |
Primary Objectives:
Condition | Intervention | Phase |
---|---|---|
Lymphoma |
Drug: Campath-1H |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52 |
Estimated Enrollment: | 30 |
Study Start Date: | March 2003 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Campath-1H
|
Drug: Campath-1H
3 mg IV On Day 1
|
Ages Eligible for Study: | up to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Issa F. Khouri, MD | 713-745-2803 |
United States, Texas | |
U.T.M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Issa F. Khouri, MD |
Principal Investigator: | Issa F. Khouri, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T.M.D. Anderson Cancer Center ( Issa F. Khouri, MD/Professor ) |
Study ID Numbers: | ID02-645 |
Study First Received: | July 20, 2007 |
Last Updated: | October 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00505921 |
Health Authority: | United States: Institutional Review Board |
T-Cell Lymphoma Lymphoma Campath-1H |
Allogenic Transplantation Stem Cell Transplant Alemtuzumab |
Lymphatic Diseases Immunoproliferative Disorders Alemtuzumab Lymphoma, T-Cell |
Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |